| pubmed-article:20507301 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0205160 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0205219 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0034606 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0442967 | lld:lifeskim |
| pubmed-article:20507301 | lifeskim:mentions | umls-concept:C0441633 | lld:lifeskim |
| pubmed-article:20507301 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20507301 | pubmed:dateCreated | 2010-7-20 | lld:pubmed |
| pubmed-article:20507301 | pubmed:abstractText | The utility of ([18F])fluoro-2-deoxy- d-glucose positron-emission tomography (FDG-PET) for predicting outcome after autologous stem cell transplantation (ASCT) for diffuse large B cell lymphoma (DLBCL) is uncertain - existing studies include a range of histological subtypes or have a limited duration of follow-up. Thirty-nine patients with primary-refractory or relapsed DLBCL with pre-ASCT PET scans were analysed. The median follow-up was 3 years. The 3-year progression-free survival (PFS) for patients with positive PET scans pre-ASCT was 35% vs. 81% for those who had negative PET scans (P = 0.003). The overall survival (OS) in these groups was 39% and 81% (P = 0.01), respectively. In a multivariate analysis, PET result, number of salvage cycles and the presence of relapsed or refractory disease were shown to predict a longer PFS; PET negativity (P = 0.04) was predictive of a longer OS. PET is useful for defining those with an excellent prognosis post-ASCT. Although those with positive scans can still be salvaged with current treatments, PET may useful for selecting patients eligible for novel consolidation strategies after salvage therapies. | lld:pubmed |
| pubmed-article:20507301 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20507301 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20507301 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20507301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20507301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20507301 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20507301 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:20507301 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:GriggAndrewA | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:SeymourJohn... | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:SzerJeffJ | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:PrinceH... | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:RobertsAndrew... | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:DickinsonMich... | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:RitchieDavidD | lld:pubmed |
| pubmed-article:20507301 | pubmed:author | pubmed-author:HoytRosemaryR | lld:pubmed |
| pubmed-article:20507301 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20507301 | pubmed:volume | 150 | lld:pubmed |
| pubmed-article:20507301 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20507301 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20507301 | pubmed:pagination | 39-45 | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:meshHeading | pubmed-meshheading:20507301... | lld:pubmed |
| pubmed-article:20507301 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20507301 | pubmed:articleTitle | Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. | lld:pubmed |
| pubmed-article:20507301 | pubmed:affiliation | Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. | lld:pubmed |
| pubmed-article:20507301 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20507301 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:20507301 | pubmed:publicationType | Multicenter Study | lld:pubmed |
